
The FDA approved adrabetadex for infantile-onset NPC based on a 55% lower risk of death vs external controls, with a boxed warning for hearing loss.
Childhood melanoma is a challenging diagnosis even for a clinician who sees pigmented skin lesions every day. The authors share their international experience with you and describe what you need to know in your practice about the rare, but real, childhood melanoma.






